Table 2.
Demographic, histologic, laboratory and clinical features of pSS patients that were evaluated for association with the serum, saliva or MSG levels of CXCL13 or NHL.
| Disease features | Association with | |
|---|---|---|
| CXCL13 levels | NHL | |
| Age on sampling | X | X |
| Age on disease diagnosis | X | |
| Age on disease onset | X | |
| Disease duration | X | X |
| Focus score | X | X |
| Ectopic germinal centers | X | X |
| Salivary Gland enlargement | X | X |
| Rheumatoid factor | X | X |
| ANA autoantibodies | X | X |
| Ro/La autoantibodies | X | X |
| C3 hypocomplementenemia | X | X |
| C4 hypocomplementenemia | X | X |
| Cryoglobulinemia | X | X |
| Hyperglobulinemia | X | X |
| Leukopenia (at sampling) | X | X |
| Lymphopenia (at sampling) | X | X |
| Neutropenia (at sampling) | X | X |
| Monoclonal gamopathy | X | X |
| Anemia (at sampling) | X | X |
| Arthralgias/arthritis | X | X |
| Arthritis | X | X |
| Palpable purpura | X | X |
| Raynaud’s phenomenon | X | X |
| Vasculitis | X | X |
| Peripheral Neuropathy | X | X |
| Pulmonary involvement | X | X |
| Liver involvement | X | X |
| Kidney involvement | X | X |
| Splenomegaly | X | X |
| Lymphadenopathy | X | X |
| ESSDAI score | X | X |
| ESSDAI score ≥5 | X | X |
| High-risk to develop NHL | X | |
| NHL | X | |
| Type of NHL (MALT) | X | |
| NHL location (MSG vs other) | X | |
X mark is used to indicate the comparisons performed.